Future outcomes and health needs of chronic hepatitis C patients after receiving antiviral therapy. (5th April 2021)

• Record Type: Journal Article
• Authors: Hsiao, Yu‐Hsuan; Chen, Wei‐Ming; Chang, Chia‐Hao; Chen, Mei‐Yen
• Is Part Of: Journal of advanced nursing. Volume 77:Number 8(2021)
• Page Start: 3370
• Page End: 3378
• Publication Date: 2021-04-05
• Subjects: cardiometabolic diseases -- chronic hepatitis C -- direct acting antiviral agents -- health promotion -- nursing; Nursing -- Periodicals; 610.7305
• DOI: 10.1111/jan.14850
• Languages: English
• ISSNs: 0309-2402

Abstract

Abstract: Aims: To study the future outcomes and health needs of chronic hepatitis C (CHC) patients after receiving direct‐acting antiviral (DAA) therapy based on the health promotion perspectives and cardiometabolic risks in a rural setting. Design: This cross‐sectional study was conducted from May to December 2019 in coastal western and southern Taiwan. Methods: We included CHC patients who were diagnosed and transferred by the gastroenterologist and hepatologist in outpatient clinics and completed DAA treatments. Data on demographic characteristics, health‐related behaviours and physiological biomarkers were collected through one‐on‐one interview using a questionnaire and from medical records obtained from a teaching hospital. Results: In total, 124 participants were enrolled. Most participants (87.1%) had no side effects and 79.8% felt satisfied after treatment. However, 62.1% had metabolic syndrome, 48.4% had hypertension and 37.9% had diabetes. Furthermore, 71.8% patients were considered to have medium‐to‐high risk based on Framingham risk scores. In the multiple regression model, after adjusting for education level, other chronic diseases were negatively associated with health‐promoting behaviours in participants. Conclusions: Although there were few side effects and most patients were satisfied after treatment, there was a high prevalence of cardiometabolic risk factors and cardiometabolic diseases and less adoption of healthy behaviours in CHC patients. Despite the small sample size, the study suggests that clinicians can reduce the burden of the aforementioned comorbidities by providing adequate treatment and individualized lifestyle modification. Impact: This study highlights that primary healthcare providers should consider the health needs of CHC patients after DAA treatment since many patients have high cardiometabolic risks, but only a few adopt a healthy lifestyle. Further studies are needed to initiate health‐promoting programs for these patients to reduce further injury to vital organs.